HE4 Combined with MDCT Imaging is a Good Marker in the Evaluation of Disease Extension in Advanced Epithelial Ovarian Carcinoma

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2012 Mar 21

PMID 22430259

Citations 14

Authors

Cecilia Midulla

Lucia Manganaro

Flavia Longo

Valentina Viggiani

Luigi Frati

Teresa Granato

Emanuela Anastasi

Affiliations

Soon will be listed here.

Abstract

The purpose of the study was to evaluate the expression of the biomarkers CA125 and HE4 combined with imaging, in patients with advanced epithelial ovarian cancer (EOC). Forty-six women with EOC were included in the study all affected with peritoneal carcinomatosis. Twenty-two of 46 patients (group I) had peritoneal carcinomatosis with small implants in single or in multiple sites (score 1); 24/46 patients (group II) had macro-nodular implants and omental thickening (score 2). High levels of CA125 (350 ± 11, mean ± SEM) have been observed in 21/22 patients of group I, and a similar value (370 ± 13) has been observed in all patients belonging to group II. HE4 positivity values (350 ± 9) have been observed in all group I patients, whereas all patients belonging to group II showed a higher value of HE4 (600 ± 12). Statistically significant differences were observed between the HE4 levels observed in group I patients in comparison with group II patients (p < 0.0001). In addition, we expressed the extension of lymph nodal disease in three scores: L1-L2-L3, and a statistically significant correlation was observed between high HE4 levels and severity of lymph nodal disease L3 (p < 0.0001). The availability of biomarkers, particularly HE4, together with sophisticated imaging techniques, strengthens the clinical relevance of this study, for the follow-up of patients with peritoneal carcinomatosis.

Citing Articles

Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses.

Jang T, Kim H, Eo W, Kim K, Lee C, Kim M J Cancer. 2023; 14(4):600-610.

PMID: 37057288 PMC: 10088533. DOI: 10.7150/jca.81174.

The Complementary Role of Imaging and Tumor Biomarkers in Gynecological Cancers: An Update of the Literature.

Anastasi E, Gigli S, Ballesio L, Angeloni A, Manganaro L Asian Pac J Cancer Prev. 2018; 19(2):309-317.

PMID: 29479951 PMC: 5980913. DOI: 10.22034/APJCP.2018.19.2.309.

Role of Galectin-3 Combined with Multi- Detector Contrast Enhanced Computed Tomography in Predicting Disease Recurrence in Patients with Ovarian Cancer.

Anastasi E, Gigli S, Santulli M, Tartaglione S, Ballesio L, Porpora M Asian Pac J Cancer Prev. 2017; 18(5):1277-1282.

PMID: 28610414 PMC: 5555535. DOI: 10.22034/APJCP.2017.18.5.1277.

Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.

Shen Y, Li L Tumour Biol. 2016; 37(11):14765-14772.

PMID: 27629144 DOI: 10.1007/s13277-016-5335-0.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Soletormos G, Duffy M, Othman Abu Hassan S, Verheijen R, Tholander B, Bast Jr R Int J Gynecol Cancer. 2015; 26(1):43-51.

PMID: 26588231 PMC: 4679342. DOI: 10.1097/IGC.0000000000000586.

References

Marin D, Catalano C, Baski M, Di Martino M, Geiger D, Di Giorgio A . 64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abdom Imaging. 2009; 35(6):694-700. DOI: 10.1007/s00261-008-9464-9. View

Verleye L, Ottevanger P, van der Graaf W, Reed N, Vergote I . EORTC-GCG process quality indicators for ovarian cancer surgery. Eur J Cancer. 2008; 45(4):517-26. DOI: 10.1016/j.ejca.2008.09.031. View

Meissnitzer M, Forstner R . [Radiological diagnostics of ovarian cancer]. Radiologe. 2011; 51(7):581-8. DOI: 10.1007/s00117-010-2120-8. View

Drapkin R, von Horsten H, Lin Y, C Mok S, Crum C, Welch W . Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65(6):2162-9. DOI: 10.1158/0008-5472.CAN-04-3924. View

Coakley F, Choi P, Gougoutas C, Pothuri B, Venkatraman E, Chi D . Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology. 2002; 223(2):495-9. DOI: 10.1148/radiol.2232011081. View

Bizzo S, Meira D, Lima J, da Silva Mororo J, Casali-da-Rocha J, Ornellas M . Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer. Int J Gynaecol Obstet. 2010; 109(2):113-7. DOI: 10.1016/j.ijgo.2009.11.021. View

Rosen D, Wang L, Atkinson J, Yu Y, Lu K, Diamandis E . Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005; 99(2):267-77. DOI: 10.1016/j.ygyno.2005.06.040. View

Lutz A, Willmann J, Drescher C, Ray P, Cochran F, Urban N . Early diagnosis of ovarian carcinoma: is a solution in sight?. Radiology. 2011; 259(2):329-45. DOI: 10.1148/radiol.11090563. View

Moore R, Brown A, Miller M, Badgwell D, Lu Z, Allard W . Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008; 110(2):196-201. PMC: 3594093. DOI: 10.1016/j.ygyno.2008.04.002. View

10.

Bharwani N, Reznek R, Rockall A . Ovarian Cancer Management: the role of imaging and diagnostic challenges. Eur J Radiol. 2011; 78(1):41-51. DOI: 10.1016/j.ejrad.2010.11.039. View

11.

Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast Jr R . Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol. 2010; 31(3):209-15. DOI: 10.1007/s13277-010-0032-x. View

12.

Boone J . Multidetector CT: opportunities, challenges, and concerns associated with scanners with 64 or more detector rows. Radiology. 2006; 241(2):334-7. DOI: 10.1148/radiol.2412060169. View

13.

Chereau E, Ballester M, Rouzier R, Coutant C, Darai E . [Advanced ovarian cancer: criteria of resectability]. Bull Cancer. 2009; 96(12):1189-97. DOI: 10.1684/bdc.2009.0985. View

14.

Ozols R . Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002; 20(5):1161-3. DOI: 10.1200/JCO.2002.20.5.1161. View

15.

van der Burg M . Advanced ovarian cancer. Curr Treat Options Oncol. 2002; 2(2):109-18. DOI: 10.1007/s11864-001-0053-1. View

16.

Kirchhoff C . Molecular characterization of epididymal proteins. Rev Reprod. 1998; 3(2):86-95. DOI: 10.1530/ror.0.0030086. View

17.

Low R . MR imaging of the peritoneal spread of malignancy. Abdom Imaging. 2007; 32(3):267-83. DOI: 10.1007/s00261-007-9210-8. View

18.

Cragun J . Screening for ovarian cancer. Cancer Control. 2011; 18(1):16-21. DOI: 10.1177/107327481101800103. View

19.

Moore R, Jabre-Raughley M, Brown A, Robison K, Miller M, Allard W . Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010; 203(3):228.e1-6. PMC: 3594101. DOI: 10.1016/j.ajog.2010.03.043. View

20.

Anastasi E, Marchei G, Viggiani V, Gennarini G, Frati L, Reale M . HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010; 31(2):113-9. DOI: 10.1007/s13277-009-0015-y. View